← Back to Search

Chemotherapy

G-GLIP plus Mitomycin C for Pancreatic Cancer (GFLIPM Trial)

Phase 2

Waitlist Available

Research Sponsored by Hirschfeld Oncology

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age 18 or older.

Histologically confirmed metastatic (Stage IV) pancreatic adenocarcinoma.

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, 3 months, 6 months, 1 year, and then annually up to 5 years.

Awards & highlights

GFLIPM Trial Summary

This trial is testing a new treatment for advanced pancreatic cancer. The researchers are combining several low-dose anti-cancer drugs with the addition of a drug called Mitomycin C. The goal is to

Who is the study for?

This trial is for adults over 18 with advanced pancreatic cancer that has spread, who have already tried one chemotherapy but need a new option. They should be expected to live more than 3 months and be able to do some daily activities on their own.Check my eligibility

What is being tested?

The study tests a low-dose mix of anti-cancer drugs (G-FLIP: Gemcitabine, Fluorouracil, Leucovorin, Irinotecan, Oxaliplatin) plus Mitomycin C in patients with stage IV pancreatic cancer to find a treatment that's both safer and more effective.See study design

What are the potential side effects?

Possible side effects include nausea, vomiting, diarrhea, fatigue, risk of infection due to lowered blood cell counts; liver or kidney function issues; and potential allergic reactions.

GFLIPM Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

My cancer is a type of pancreatic cancer that has spread.

Select...

My first cancer treatment did not work.

Select...

I can take care of myself and perform daily activities.

GFLIPM Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, 3 months, 6 months, 1 year, and then annually up to 5 years.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, 3 months, 6 months, 1 year, and then annually up to 5 years.

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 3 months, 6 months, 1 year, and then annually up to 5 years. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Overall Survival

Response Rate

GFLIPM Trial Design

1Treatment groups

Experimental Treatment

Group I: G-GLIP plus Mitomycin CExperimental Treatment1 Intervention

G-FLIP: Gemcitabine, Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin every 2 weeks plus Mitomycin C every 4 weeks

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

Hirschfeld OncologyLead Sponsor

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the combination of G-GLIP and Mitomycin C received official approval from the FDA?

"Based on our assessment at Power, the safety profile of G-GLIP plus Mitomycin C is rated as 2. This rating reflects that although there is limited data supporting its safety, no evidence has been established regarding its efficacy in this Phase 2 trial."

Answered by AI

Are there any available positions for participants in this research study?

"As per the information available on clinicaltrials.gov, this particular trial is not currently open for patient recruitment. The study was initially posted on February 1st, 2024 and last updated on January 22nd, 2024. However, it's worth noting that there are currently 709 other trials actively recruiting patients at this time."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Clinical Trial Evaluating Low Dose G-FLIP Plus Mitomycin C for Stage IV Pancreatic Cancer

2024. "Clinical Trial Evaluating Low Dose G-FLIP Plus Mitomycin C for Stage IV Pancreatic Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06233877.